Breast cancer advocate Jody Schoger shares her experiences of presenting a poster and attending sessions at the 2014 Breast Cancer Symposium.
A large Canadian study finds that simply adding a doctor-signed letter to standard postcard reminders increases the chance that women will have their overdue mammogram screenings.
Learn how Angelina Jolie sharing her decision to have a preventive double mastectomy because she was a carrier of the BRCA mutation affected genetic counseling referrals and genetic testing rates at a Canadian cancer center.
New Insight on the Factors Affecting Local and Regional Recurrence from the 2014 Breast Cancer Symposium
Learn more about the results of a large study that has identified two factors that may help predict the chance that breast cancer will come back in the breast or nearby areas better than the cancer’s stage.
Get highlights of two studies that provide insight into why some women with early-stage breast cancer choose to have a double mastectomy and the risk of complications they may experience after this surgery.
What would it be like to meet the inventor of the investigational drug that is keeping you alive? Janet Freeman-Daily found out firsthand at the 2014 ASCO Annual Meeting.
Prostate cancer patient advocate Alvin Chin describes how his experiences in Chicago satisfied his “sweet tooth” for relevant and important cancer information.
Research Highlights on Immunotherapy for Melanoma and Cervical Cancer From the 2014 ASCO Annual Meeting
Activating and amplifying the body’s immune response to cancer is an exciting area of research. See how it is being used to better treat advanced or high-risk melanoma and cervical cancer in these four studies presented in Chicago today.
Get highlights of four pivotal studies that reveal new ways to optimize commonly used chemotherapy, hormone therapy, and newer targeted drugs, and answer critical questions about the effectiveness of two common treatment regimens for advanced colorectal cancer.
Learn more about four studies that show the potential of new targeted therapies for advanced ovarian, lung, and thyroid cancers and chronic lymphocytic leukemia.